The Difference Between Besponsa and Blinatumomab

Besponsa and Blinatumomab are two drugs used to treat leukemia. They have significant differences in treatment mechanisms, indications, drug types and usage scenarios. Here’s a detailed comparison of the differences between these two drugs:

1. Drug type:

Olintuzumab/Olintuzumab (Besponsa) is a monoclonal antibody drug. It is an antibody against a specific protein (CD22antigen) and is used to treat B-cell Acute Lymphoblastic Leukemia (B-ALL ).

Blinatumomab is a biological agent and a type of biological therapy. It is a bispecific T cell-dependent chimeric antibody (BiTE) designed to connect T cells and B cells, used to treat acute lymphoblastic leukemia, including B cell type and T cell type acute lymphoblastic leukemia (T-ALL).

2. Mechanism of action:

Olintuzumab/Olintuzumab (Besponsa)'s mechanism of action primarily involves targeting the CD22 antigen, which is a protein on the surface of lymphocytes. Ointozumab/Ointozumab binds to CD22, thereby interfering with the growth and survival of leukemia cells and helping to reduce the progression of the disease.

Blinatumomab works through a different mechanism. It is a bispecific antibody that binds to the CD19 antigen on the surface of B cells at one end and the other end to the CD3 antigen on the surface of T cells. This connection prompts TT cells to recognize and attack leukemia cells, similar to what prompts your own immune system.

3. Indications:

Oplusintuzumab/Olintuzumab（Besponsa） It is mainly used to treat adult B-cell acute lymphoblastic leukemia (B-ALL), especially patients who are resistant to traditional treatments or have relapsed.

Blinatumomab Indicated for the treatment of multiple subtypes of acute lymphoblastic leukemia, including B-cell and T-cell acute lymphoblastic leukemia in adults and children leukemia, and a specific subtype called pre-B-cell acute lymphoblastic leukemia (Pre-B-ALL).

4. Method of administration:

Olintuzumab/Olintuzumab (Besponsa) is a drug given by intravenous injection, usually under the supervision of a hospital or medical facility.

Blinatumomab is also given intravenously, but it is usually given as a continuous infusion and requires a special pump system.

5. Use situations and treatment strategies:

Ogaintozumab/Ointozumab (Besponsa) is usually used in B-ALL patients, especially in patients who have failed or developed resistance to traditional treatments, as first-line treatment or as part of relapse treatment.

Blinatumomab is commonly used in various acute lymphoblastic leukemia subtypes, including Bcell, Tcell, and preBcell. It is commonly used to treat relapsed or refractory conditions and in preparation for bone marrow transplantation.

6. Adverse reactions:

Originutuzumab/Ointuzumab (Besponsa) Common adverse reactions include fever, nausea, vomiting, headache, fatigue, abnormal liver function, etc.

Common adverse reactions of Blinatumomab (Blinatumomab) include fever, chills, headache, nausea, vomiting, skin reactions, neurological symptoms, etc. Due to its mechanism of action, belintuzumab may induce immune-related adverse reactions, such as Cytokine Release Syndrome, CRS and neurotoxicity.

To sum up, Ogaintuzumab/Ointuzumab and belintuzumab are two drugs used to treat leukemia. They have obvious differences in many aspects, including mechanism of action, indications, drug types, administration methods and adverse reactions. Physicians often choose appropriate treatment options based on the patient's specific situation and type of disease to maximize treatment effectiveness and reduce the risk of adverse reactions. Therefore, patients should receive appropriate treatment under the guidance of a doctor.

Oplusintuzumab/OlintuzumabIt has been launched in China, but it is not included in medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.